Navigation Links
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials
Date:11/19/2009

siRNA by advancing its clinical-stage programs, and our momentum is accelerating as we enrich the Company's pipeline and bring more product candidates into the clinic," said Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark Pharmaceuticals. "Over the next 15 months, we anticipate at least one program may proceed into Phase 3 registration studies, we will report data from multiple clinical studies and we plan to file our fifth IND. We have demonstrated we have the right team and the right strategy, and we are excited about the Company's future."

Dr. Shai Erlich, Quark's Chief Medical Officer, stated, "Quark's discovery and development efforts remain focused on the goal of bringing novel and clinically relevant therapeutic options to health care providers. We do this by addressing molecular pathways that previously were not accessible to more traditional forms of pharmaceutical modulation. Quark is generating novel siRNA drug candidates and is pursuing a variety of delivery mechanisms to expand the scope of potential disease applications while eliminating the need to depend on extensive drug modifications and elaborate formulations that could reduce the therapeutic index for patients. To date, preliminary results from Quark's Phase 1 clinical studies have shown few adverse drug reactions and no treatment emergent dose-limiting toxicities. I look forward to the next stage when the company reports completed study results findings in a range of disease indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc., is a leader in the discovery and development of novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. The Company's technology platform includes novel disease targets and siRNA structures and chemistry, providing Quark with freedom to operate in the siRNA intellectual property ar
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
2. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
3. Quark Pharmaceuticals Presents at Asia TIDES Conference
4. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
5. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
6. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
7. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
11. Quark Pharmaceuticals Appoints New Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with the ... as a later starter. In 2012, the size of ... billion, with the proportion worldwide soaring to 16.3%. It is ... will continue its growth rate by around 20% in the ... to roughly RMB25 billion. An integrated membrane industrial ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: ... it has completed the previously announced acquisition of BMP ... stockholders held today, BMP Sunstone stockholders approved the adoption ... Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, ...
... Conn., Feb. 24, 2011 Mira Dx announced today that ... acceptance of a pivotal breast cancer study in the January ... BRCA1 coding sequence mutations are associated with breast ... less than 5% of breast cancer risk. The research identified ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2
(Date:12/19/2014)... Slone Partners , a national ... information technology, and laboratory testing industries, has promoted ... Officer. The announcement comes after a year of ... presence in Boston and several new additions to ... the client experience," said Adam Slone, Chief Executive ...
(Date:12/19/2014)... Dallas, TX (PRWEB) December 19, 2014 ... current state of the global Gliquidone industry with a ... statistics on the market status of the Gliquidone manufacturers ... for companies and individuals interested in the industry. , ... industry including its definition, applications and manufacturing technology. Then, ...
(Date:12/19/2014)... 19, 2014 The Hermitage Club ... in Southern Vermont’s Deerfield Valley, announced today that it ... classic rock songs. , Three time Grammy Award ... private concert followed by a trail naming ceremony. Hermitage ... names include: “I’m Alright” the theme song for the ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- A new study suggests ... to severe hot flashes and night sweats -- and ... Hot flashes are common during menopause, affecting about 60 ... affect women after menopause, since they then face a ... findings suggest women who exhibit moderate or severe menopausal ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... to high levels of air pollution late in pregnancy may ... suggests. Researchers found that of nearly 1,800 U.S. women ... the most air pollution during pregnancy were twice as likely ... during the third trimester, specifically, showed the strongest correlation to ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... by researchers at the University of Exeter Peninsula College of ... blood pressure between arms could be a useful indicator of ... findings add support to the calls for both-arm blood pressure ... published in The Lancet online today (30th January) ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- A ... insight into whether patients are at high risk of a ... The test, which is currently available, could help ... the cancer from returning. There are caveats: The test ...
... 27, 2012 An itch is just an itch. Or ... professor of dermatology at Wake Forest Baptist Medical Center and ... itch feels is related to the itch,s location. While ... analysis of itch relief at different body sites and related ...
... News) -- Positive reinforcement, such as receiving small, unexpected ... to help patients with high blood pressure take their ... black Americans. The findings are significant because poor ... death, the researchers from the Center for Healthful Behavior ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) ... and cervical cancers still fall below national targets, federal health ... were being screened for breast cancer, below the target of ... women, while the target is 93 percent, and for colon ...
... , THURSDAY, Jan. 26 (HealthDay News) -- New genetic ... menopause have been identified by an international team of ... a gene on a chromosome) linked with immune function ... menopause begins, said the researchers from the Boston University ...
Cached Medicine News:Health News:2-arm blood pressure check indicator for risk from heart disease or death 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Body location plays part in scratching pleasure 2Health News:Positive Reinforcement May Help Patients Take Their Meds 2Health News:Too Few Americans Getting Screened for Common Cancers: CDC 2Health News:Too Few Americans Getting Screened for Common Cancers: CDC 3Health News:Factors Linked to Age of Onset of Menopause Identified 2
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... line of flowmeters, available in oxygen, air, heliox and ... variety of calibrations to best suit your application. With ... in use, the Amvex Flowmeter is a user friendly ... I. For Power Take-Off add PT to the end ...
... available in oxygen, air, heliox and CO 2 . ... to best suit your application. With color coded labels ... Amvex Flowmeter is a user friendly device., ,For ... Take-Off add PT to the end of the part ...
0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
Medicine Products: